Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 72, n° 2
pages 314-320 (février 2015)
Doi : 10.1016/j.jaad.2014.10.023
accepted : 20 October 2014
Original Articles

Voriconazole phototoxicity in children: A retrospective review
 

Johanna Sheu, MS a, b, Elena B. Hawryluk, MD, PhD a, b, Dongjing Guo, MPH c, d, Wendy B. London, PhD a, c, d, Jennifer T. Huang, MD a, b, d,
a Harvard Medical School, Boston, Massachusetts 
b Dermatology Program, Division of Allergy and Immunology, Department of Medicine, Boston Children's Hospital, Boston, Massachusetts 
c Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts 
d Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 

Reprint requests: Jennifer T. Huang, MD, Dermatology Program, Boston Children's Hospital, Fegan Sixth Floor, 300 Longwood Ave, Boston, MA 02115.
Abstract
Background

Voriconazole, an antifungal agent, is associated with various cutaneous reactions, including phototoxicity, accelerated photoaging, and skin cancer. Incidence and risk factors for these reactions in children have not been well described.

Objective

We sought to determine the incidence of and factors associated with phototoxic reactions and nonmelanoma skin cancer in pediatric patients treated with voriconazole.

Methods

This was a retrospective analysis of 430 pediatric patients treated with voriconazole between 2003 and 2013 at Boston Children's Hospital.

Results

Incidence of phototoxicity was 20% in all children treated with voriconazole and 47% in children treated for 6 months or longer. Factors associated with phototoxicity included white race, cystic fibrosis, cumulative treatment time, and cumulative dose. Four patients (1%) had nonmelanoma skin cancer; all experienced a phototoxic reaction during voriconazole treatment. Of those with phototoxicity, 5% were discontinued on voriconazole, 6% were referred to dermatology, and 26% received counseling about sun protection from their primary physician.

Limitations

Our study is limited by its retrospective design and potential referral bias associated with a tertiary-care center.

Conclusions

Voriconazole-associated phototoxicity is relatively common in children and may lead to nonmelanoma skin cancer. However, those with phototoxic reactions are often continued on therapy, rarely referred to dermatology, and infrequently counseled on sun protection.

The full text of this article is available in PDF format.

Key words : nonmelanoma skin cancer, pediatrics, photosensitivity, phototoxicity, squamous cell cancer, voriconazole



 Funding sources: None.
 Conflicts of interest: None declared.



© 2014  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline